We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:
A company with a treatment of complex perianal fistula in patients with Crohn's disease, with orphan drug status, in a multinational Ph III clinical trial, available for licensing.
A company with novel monoclonal antibody targeting HGF, ready for Ph II, with excellent safety and indication of activity in gastric cancer, with dominant IP position, available for licensing.
An oral, Ph III, GI orphan drug opportunity, for the treatment of Familial Adenomatous Polyposis, with statistically significant positive Ph III data in a related indication, available for licensing in the US and ex EU/JP territories.
A medical device company with an approved, minimally invasive device for reconstructive and cosmetic cartilage surgery, available for sale/licensing.